Mace

(redirected from Major Adverse Cardiovascular Events)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.

Mace

A unit of weight in Taiwan approximately equivalent to 3.75 grams. It is used primarily in the sale of bulk foodstuffs.
References in periodicals archive ?
The trial assessed the effect of Praluent on the occurrence of major adverse cardiovascular events in patients who had suffered an acute coronary syndrome event 1-12 months before enrolling in the study, and who were already subjected to maximally-tolerated statins.
The primary safety objective is to evaluate the incidence of major adverse cardiovascular events (MACE), defined as cardiovascular death, myocardial infarction or stroke.
Kaplan-Meier analysis of major adverse cardiovascular events in the full study sample (A) and in participants with BNP >50 pg/mL(B).
A low circulating active clopidogrel metabolite causes a diminished platelet response to treatment leading to higher rates of major adverse cardiovascular events [4, 9].
The article is entitled South Asian Ethnicity as a Risk Factor for Major Adverse Cardiovascular Events After Renal Transplantation.
Joint effects of N-terminal pro-B-type-natriuretic peptide and C-reactive protein vs angiographic severity in predicting major adverse cardiovascular events and clinical restenosis after coronary angioplasty in patients with stable coronary artery disease.
Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.
Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.
com) is a randomized, double-blind, placebo-controlled cardiovascular outcomes trial evaluating the occurrence of major adverse cardiovascular events (MACE) in patients participating in the study.
Amarin announced that its REDUCE-IT cardiovascular outcomes study has reported and documented more than 90% of the targeted 1,612 primary major adverse cardiovascular events.
Under the company's FOURIER trial in 27,564-patient, the Repatha cardiovascular outcomes study demonstrated that adding Repatha to optimised statin therapy resulted in a statistically significant 20% reduction in major adverse cardiovascular events (MACE) represented in the key secondary composite endpoint of time to first heart attack, stroke or cardiovascular death.
Full browser ?